FdaApplication
BLA 761234
Identifiers
- fda_app_no: BLA761234
Properties
| Property | Value |
|---|---|
| applicant_name | Bristol-Myers Squibb Company |
| application_type | BLA |
| approval_date | 2022-03-18 |
Revenue by product
OPDUALAG
| Period | Revenue |
|---|---|
| Q2 2026 | $349.0M |
| Q1 2026 | $295.0M |
| Q4 2025 | $350.0M |
| Q3 2025 | $299.0M |
| Q2 2025 | $284.0M |
| Q1 2025 | $252.0M |
| Q4 2024 | $254.0M |
| Q3 2024 | $233.0M |
| Q2 2024 | $235.0M |
| Q1 2024 | $206.0M |
| Q4 2023 | $190.0M |
| Q3 2023 | $166.0M |
| Q2 2023 | $154.0M |
| Q1 2023 | $117.0M |
| Q4 2022 | $104.0M |
| Q3 2022 | $84.0M |
| Q2 2022 | $58.0M |
| Q1 2022 | $6.0M |
| Q4 2021 | $0.0M |
| Q3 2021 | $0.0M |
| Q2 2021 | $0.0M |
| Q1 2021 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| OPDUALAG | NIVOLUMAB; RELATLIMAB-RMBW | 240MG, 80MG/20ML (12MG, 4MG/ML) | Injection |
1 product